James Leal - Aug 27, 2021 Form 4 Insider Report for TANDEM DIABETES CARE INC (TNDM)

Role
SVP, Operations
Signature
s/ David B. Berger, Attorney-in-Fact for James A. Leal
Stock symbol
TNDM
Transactions as of
Aug 27, 2021
Transactions value $
-$12,741
Form type
4
Date filed
8/31/2021, 04:38 PM
Previous filing
Jul 29, 2021
Next filing
Sep 9, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TNDM Common Stock Options Exercise $0 +309 +8.59% $0.00 3.91K Aug 27, 2021 Direct
transaction TNDM Common Stock Tax liability $0 -154 -3.94% $0.00 3.75K Aug 27, 2021 Direct F1
transaction TNDM Common Stock Options Exercise $85.9K +1.67K +44.44% $51.50 5.42K Aug 27, 2021 Direct F2
transaction TNDM Common Stock Sale -$166K -1.5K -27.69% $110.59 3.92K Aug 27, 2021 Direct F3, F4
transaction TNDM Common Stock Sale -$18.6K -167 -4.26% $111.12 3.75K Aug 27, 2021 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TNDM Restricted Stock Unit Options Exercise $0 +309 +9.97% $0.00 3.41K Aug 27, 2021 Common Stock 309 Direct F5, F6, F7
transaction TNDM Stock Option Options Exercise $85.9K +1.67K +5.88% $51.50 30K Aug 27, 2021 Common Stock 1.67K $51.50 Direct F8, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.
F2 Represents shares of common stock received upon exercise of a stock option award.
F3 The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2020.
F4 The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $110.00 to $110.98. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.
F5 Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan (the 2013 Plan).
F6 Each RSU represents a contingent right to receive one share of common stock of the Company.
F7 RSU vested as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/27/2021, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter.
F8 The options vested as to twenty-five (25%) of the underlying shares on 2/15/2020, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter, subject to the terms of Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the "2013 Plan").
F9 The expiration date for these options is 10 years from the date of grant.